| Literature DB >> 35369275 |
Tanita Suttichaimongkol1, Manoon Mitpracha2, Kawin Tangvoraphonkchai1, Phuangphaka Sadee1, Kittisak Sawanyawisuth1, Wattana Sukeepaisarnjaroen1.
Abstract
Aim: This study aimed to evaluate if clinical or radiographic findings can be used for hepatocellular carcinoma (HCC) diagnosis particularly in high-risk patients.Entities:
Keywords: cirrhosis; hepatitis virus; size
Year: 2022 PMID: 35369275 PMCID: PMC8965803 DOI: 10.2144/fsoa-2021-0108
Source DB: PubMed Journal: Future Sci OA ISSN: 2056-5623
Baseline characters of patients with high risk for hepatocellular carcinoma (HCC) categorized by diagnosis of HCC.
| Factors | HCC (n = 219) | Non-HCC (n = 41) | p-value |
|---|---|---|---|
| Age, years | 59 (54–64) | 57 (52–61) | 0.143 |
| Male sex, n (%) | 181 (82.60) | 30 (73.20) | 0.154 |
| Etiology | 0.686 | ||
| HBV | 83 (37.90) | 15 (36.60) | |
| HCV | 94 (42.90) | 20 (48.00) | |
| HBV plus HCV | 4 (1.80) | 2 (4.90) | |
| NAFLD | 13 (5.90) | 1 (2.40) | |
| ALD | 24 (11.00) | 3 (7.30) | |
| AIH | 1 (0.50) | 0 | |
| Co-morbid diseases | 0.471 | ||
| None | 164 (74.90) | 29 (70.70) | |
| Diabetes | 29 (13.20) | 9 (22.00) | |
| Hypertension | 10 (4.60) | 2 (4.90) | |
| Cirrhosis | 217 (99.09) | 39 (95.12) | 0.036 |
| Child-Pugh score A | 174 (79.50) | 37 (90.20) | |
| Child-Pugh score B | 34 (15.50) | 2 (4.90) | |
| Child-Pugh score C | 9 (4.10) | 0 |
HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; NAFLD: Nonalcoholic fatty liver disease; ALD: Alcoholic liver disease; AIH: Autoimmune hepatitis.
Laboratory results of patients with high risk for hepatocellular carcinoma (HCC) categorized by diagnosis of HCC.
| Factors | HCC (n = 219) | Non-HCC (n = 41) | p-value |
|---|---|---|---|
| Platelet x 103/mm3 | 149 (101–224) | 130 (110–192) | 0.388 |
| Creatinine (mg/dl) | 0.94 (0.79–1.16) | 0.92 (0.81–1.10) | 0.695 |
| Prothrombin time (s) | 12.50 (11.60–13.50) | 11.70 (11.00–12.50) | <0.001 |
| Albumin (g/dl) | 3.80 (3.30–4.30) | 4.40 (3.70–4.70) | <0.001 |
| Bilirubin (mg/dl) | 1 (0.70–1.80) | 0.70 (0.60–1.00) | 0.003 |
| Alanine aminotransferase (U/l) | 55 (31–88) | 32 (21–72) | 0.005 |
| Aspartate transaminase (U/l) | 82 (45–145) | 42 (23–67) | <0.001 |
| Alpha-fetoprotein (IU/ml) | 118.60 (10.20–3326.60) | 4.1 (1.90–14.60) | <0.001 |
| Radiographic findings | |||
| Number of liver nodules, n (%) | 0.012 | ||
| 1 | 129 (58.90) | 27 (65.90) | |
| 2 | 44 (20.10) | 2 (4.90) | |
| 3 | 7 (3.20) | 5 (12.20) | |
| ≥4 | 39 (17.80) | 7 (17.10) | |
| Largest size, n (%) | <0.001 | ||
| ≤3 cm | 83 (37.90) | 39 (95.10) | |
| >3 cm | 136 (62.10) | 2 (4.90) | |
| Portal vein invasion, n (%) | <0.001 | ||
| No invasion | 140 (63.93) | 41 (100) | |
| Main portal vein invasion | 56 (25.57) | 0 | |
| Nonmain portal vein invasion | 23 (10.50) | 0 | |
Data presented as median (range) unless indicated otherwise.
HCC: Hepatocellular carcinoma.
Figure 1.Study flow chart of patients with high risk for hepatocellular carcinoma and numbers of patients with portal vein invasion and size of over 3 cm.
HCC: Hepatocellular carcinoma; PVI: Portal vein invasion.
Factors predictive of hepatocellular carcinoma in patients with high risk for hepatocellular carcinoma.
| Factors | Unadjusted odds ratio (95% CI) | Adjusted odds ratio (95% CI) |
|---|---|---|
| Age | 1.03 (0.99, 1.08) | 1.05 (0.99, 1.01) |
| Sex | 1.74 (0.80, 3.78) | 1.65 (0.51, 5.31) |
| HBV or HCV infection | 0.51 (0.17, 1.53) | 0.72 (0.17, 3.04) |
| Child–Pugh score | 1.25 (0.65, 2.37) | 2.22 (0.30, 16.49) |
| Prothrombin time | 1.62 (1.20, 2.18) | 1.38 (0.86, 2.23) |
| Albumin | 0.32 (0.18, 0.58) | 0.92 (0.35, 2.40) |
| Bilirubin | 1.97 (1.14, 3.39) | 1.23 (0.76, 1.99) |
| ALT | 1.01 (1.00, 1.02) | 1.00 (0.98, 1.01) |
| AST | 1.01 (1.00, 1.02) | 0.99 (0.99, 1.01) |
| AFP | 1.00 (1.00, 1.00) | 1.00 (0.99, 1.01) |
| Number of mass | 0.99 (0.74, 1.33) | 0.78 (0.51, 1.18) |
| Largest mass size, cm | 3.84 (2.23, 6.59) | 3.37 (1.89, 6.02) |
HBV: Hepatitis B virus; HCV: Hepatitis C virus; ALT: Alanine aminotransferase; AST: Aspartate transaminase; AFP: Alpha-fetoprotein.
Figure 2.A receiver-operating characteristic curve of largest mass size for hepatocellular carcinoma in patients with high risk for hepatocellular carcinoma.